CSIMarket
 


Larimar Therapeutics Inc   (LRMR)
Other Ticker:  
 

Larimar Therapeutics Inc 's Quick Ratio

LRMR's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Larimar Therapeutics Inc 's Cash & cash equivalent, this led to improvement in Larimar Therapeutics Inc 's Quick Ratio to 14.58, above Larimar Therapeutics Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 59 other companies have achieved higher Quick Ratio than Larimar Therapeutics Inc in third quarter 2023. While Quick Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 167 to 195.

Explain Quick Ratio?
How much Cash & cash equivalents LRMR´s has?
What are LRMR´s Current Liabilities?


LRMR Quick Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change -30.38 % -5.75 % -9.73 % 21.02 % -8.6 %
Y / Y Cash & cash equivalent Change -23.34 % 89.72 % 78.26 % 68.95 % 59.82 %
Quick Ratio MRQ 14.58 14.32 13.92 11.06 13.24
LRMR's Total Ranking # 195 # 167 # 254 # 202 # 296
Seq. Current Liabilities Change -9.86 % -9.18 % -25.18 % 13.64 % 22.04 %
Seq. Cash & cash equivalent Change -8.26 % -6.57 % -5.83 % -5.03 % 127.04 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 60
Healthcare Sector # 96
Overall Market # 195


Quick Ratio Statistics
High Average Low
32.72 12.4 5.02
(Jun 30 2014)   (Sep 30 2019)




Financial Statements
Larimar Therapeutics Inc 's Current Liabilities $ 7 Millions Visit LRMR's Balance sheet
Larimar Therapeutics Inc 's Cash & cash equivalent $ 96 Millions Visit LRMR's Balance sheet
Source of LRMR's Sales Visit LRMR's Sales by Geography


Cumulative Larimar Therapeutics Inc 's Quick Ratio

LRMR's Quick Ratio for the trailling 12 Months

LRMR Quick Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth -30.38 % -5.75 % -9.73 % 21.02 % -8.6 %
Y / Y Cash & cash equivalent TTM Growth -23.34 % 89.72 % 78.26 % 68.95 % 59.82 %
Quick Ratio TTM 13.2 12.96 11.42 9.82 8.96
Total Ranking TTM # 142 # 165 # 226 # 327 # 413
Seq. Current Liabilities TTM Growth -9.86 % -9.18 % -25.18 % 13.64 % 22.04 %
Seq. Cash & cash equivalent TTM Growth -8.26 % -6.57 % -5.83 % -5.03 % 127.04 %


On the trailing twelve months basis Current Liabilities decreased faster than Larimar Therapeutics Inc 's average Cash & cash equivalent, this led to increase in in Larimar Therapeutics Inc 's Quick Ratio to 13.2, above LRMR average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 473 other companies have achieved higher Quick Ratio than Larimar Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 110, from total ranking during the twelve months ending second quarter 2023 at 2080.

Explain Quick Ratio?
How much Cash & cash equivalents LRMR´s has?
What are LRMR´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 474
Healthcare Sector # 949
Within the Market # 195


trailing twelve months Quick Ratio Statistics
High Average Low
13.45 10 5.94
(Dec 31 2017)   (Mar 31 2020)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Nuvation Bio Inc   38.37 $ 619.339  Millions$ 16.143  Millions
Merrimack Pharmaceuticals Inc  38.34 $ 18.904  Millions$ 0.493  Millions
Xbiotech Inc   38.19 $ 202.191  Millions$ 5.294  Millions
Morphic Holding inc   37.57 $ 725.067  Millions$ 19.298  Millions
Eliem Therapeutics Inc   37.03 $ 107.433  Millions$ 2.901  Millions
Royalty Pharma Plc  35.91 $ 941.748  Millions$ 26.222  Millions
Rayzebio Inc   34.09 $ 540.169  Millions$ 15.847  Millions
Cymabay Therapeutics Inc   31.72 $ 438.778  Millions$ 13.831  Millions
Atea Pharmaceuticals Inc   31.50 $ 595.126  Millions$ 18.893  Millions
Greenwich Lifesciences Inc   30.76 $ 9.144  Millions$ 0.297  Millions
Verona Pharma Plc  29.80 $ 257.366  Millions$ 8.636  Millions
Aprea Therapeutics Inc   29.39 $ 25.354  Millions$ 0.863  Millions
Theseus Pharmaceuticals Inc   29.29 $ 205.122  Millions$ 7.003  Millions
Viking Therapeutics Inc   28.75 $ 376.241  Millions$ 13.086  Millions
Karuna Therapeutics Inc   27.40 $ 1,341.510  Millions$ 48.968  Millions
Atossa Therapeutics Inc   27.33 $ 94.141  Millions$ 3.444  Millions
Disc Medicine Inc   25.70 $ 370.541  Millions$ 14.416  Millions
Belite Bio Inc  24.27 $ 88.157  Millions$ 3.633  Millions
Janux Therapeutics Inc   24.17 $ 349.712  Millions$ 14.471  Millions
Bright Minds Biosciences Inc   24.16 $ 5.197  Millions$ 0.215  Millions
Design Therapeutics Inc   23.48 $ 290.940  Millions$ 12.390  Millions
Lixte Biotechnology Holdings Inc   23.08 $ 5.106  Millions$ 0.221  Millions
Diamedica Therapeutics Inc   22.23 $ 46.465  Millions$ 2.090  Millions
Terns Pharmaceuticals Inc   22.06 $ 266.600  Millions$ 12.087  Millions
Cyteir Therapeutics Inc   21.65 $ 129.242  Millions$ 5.969  Millions
Ars Pharmaceuticals Inc   21.64 $ 241.902  Millions$ 11.180  Millions
Xenon Pharmaceuticals Inc   21.28 $ 526.674  Millions$ 24.744  Millions
Tyra Biosciences Inc   21.25 $ 215.652  Millions$ 10.147  Millions
Astria Therapeutics inc   21.23 $ 188.806  Millions$ 8.894  Millions
Sagimet Biosciences inc   20.59 $ 101.842  Millions$ 4.946  Millions

Date modified: 2023-11-16T18:59:45+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com